Skip to content
Search

Latest Stories

GPhC Council to increase renewal fees by 7.5% from April 2024

The council declared a rise in the renewal fees for pharmacy workers starting next year

The General Pharmaceutical Council (GPhC) has decided to increase the renewal fees of pharmacists, pharmacy technicians, and pharmacy premises by 7.5% from April 2024.


The pharmacy technician's renewal fee will see an increase by £9 from £121 to £130, pharmacists fees from £257 to £276, and pharmacy premises from £365 to £392.

The following decision came even despite the renewal fees being frozen for individual registrants since 2019 and for pharmacy premises since 2021.

This move was facilitated through cost savings measures like using financial reserves and downsizing to a smaller office.

However, the council confirmed that the fee hike is due to higher rates of inflation, increase in utility bills and supplier costs.

Duncan Rudkin, Chief Executive and Registrar of the GPhC, said: “We know that these are challenging times and that this increase will come as unwelcome news to those we regulate. But to be effective in our role of protecting the public we need to make sure the fees we charge cover the cost of regulation going forward.”

Giving reasons for the fee rise, Rudkin stated that they are subject to the same “inflationary pressures and financial challenges” as those they regulate.

The Council concluded that it took the "difficult decision" to raise the fees in order to be in a position to continue to carry out regulatory work.

“We are working in a changing environment and have to adapt accordingly and regulate in a world where pharmacy is evolving at pace,” Rudkin said.

“This will continue to lead to significant changes in the scope and complexity of our work, on top of the major projects we are already undertaking such as reforms to initial education and training; post-registration assurance of practice, and the development of new standards following legislative change.

“In taking this difficult decision, we are ensuring we can carry out our statutory duties and continue to ensure patients and the public receive safe and effective pharmacy care and have trust in pharmacy, now and in the future,” he added.

The Council received 7129 responses to the consultation on fees, which closed on 8 August 2023, and many of them disagreed with the proposed increases.

Responding to the feedback on paying fees differently, the GPhC said that it will be “looking into the feasibility of offering a monthly direct debit option, in addition to the current option to pay by quarterly direct debit.”

In the near future, the GPhC is planning to move towards a more regular and incremental approach to fee setting to provide more certainty about future fees and enable any fee changes to be introduced more gradually in the future.

More For You

Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less
Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less